In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gryphon Therapeutics Inc.

www.gryphonrx.com

Latest From Gryphon Therapeutics Inc.

SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 2 of 2)

On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.

BioPharmaceutical China

SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 1 of 2)

On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.

BioPharmaceutical China

Licensing Trends By Clinical Phase

We revisit a chart from 1997 examining deal volume by clinical phase to highlight the changing landscape of late stage licensing.
BioPharmaceutical Business Strategies

Roche Bucks the Trend, with Early-Stage Deals

Unlike many of its Big Pharma brethren, for Roche, preclinical and Phase I licensing has been a favored deal-making formula: collaborate with a small company on the development of a compound at or before clinical proof-of-concept, drive the program using its development expertise, and retain rights to follow-on products with which it can repeat the process, presumably having now lowered both compound and clinical risk. Its deal with Kosan is the latest example.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Gryphon Sciences
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gryphon Therapeutics Inc.
  • Senior Management
  • Friedhelm Blobel, PhD, Pres. & CEO
    Ronald E Susek, PhD, VP, Bus. Dev.
  • Contact Info
  • Gryphon Therapeutics Inc.
    Phone: (560) 952-7714
    250 East Grand Ave.
    Suite 90
    S. San Francisco, CA 94080-3606
    USA
UsernamePublicRestriction

Register